Immuneering Corp — Director's Dealing 2021

Jul 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-07-29

Reporting Person: Hall Brett Matthew (Chief Scientific Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$3.01	2029-02-24	Class A Common Stock (91000)		Direct
Stock Option	$3.01	2029-12-15	Class A Common Stock (201600)		Direct
Stock Option	$9.74	2031-05-05	Class A Common Stock (175000)		Direct
Series A Preferred Stock	$		Class A Common Stock (1636)		Direct
Series B Preferred Stock	$		Class A Common Stock (3404)		Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on May 5, 2019 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.

F2: The option vests and becomes exercisable as to 25% of the underlying shares on November 1, 2020 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.

F3: The option vests and becomes exercisable as to 25% of the underlying shares on May 4, 2022 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.

F4: Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.